Short at­tack tar­gets one of the fa­vorites now shar­ing the lead in the pop­u­lar KRAS drug de­vel­op­ment race

6 years ago
R&D

EMA up­dates on reg­u­la­to­ry ex­pec­ta­tions amid Covid-19

6 years ago
FDA+
Coronavirus

Data­vant boots up a big Covid-19 reg­istry — look­ing to shine a light on virus spread, im­pact and most ef­fec­tive ...

6 years ago
R&D
Coronavirus

An­oth­er PhI­II win in hand, Cara aims straight for pri­or­i­ty re­view of 'break­through' pru­ri­tus drug

6 years ago
R&D

Covid-19 roundup: The pan­dem­ic bear — You think a vac­cine and herd im­mu­ni­ty are just months away? Dream on, says ...

6 years ago
Coronavirus

Still no ad­u­canum­ab fil­ing and an in-house gath­er­ing trig­gered a health dis­as­ter, but Bio­gen's CEO nev­er­the­less took ...

6 years ago
People

Es­pe­ri­on strikes Japan deal for 'goldilock­s' cho­les­terol drug, bags $60M cash as pan­dem­ic forces vir­tu­al US roll­out

6 years ago
Deals

Sofinno­va Telethon Fund backs Nal­dini's gene ther­a­py biotech; ORIC prices $75M IPO

6 years ago
News Briefing

Piv­otal da­ta sug­gest clean safe­ty pro­file, po­ten­cy could set Idor­si­a's sleep­ing pill apart

6 years ago
R&D

Ex­elix­is lands PhI­II kid­ney can­cer win with Bris­tol My­ers in their hunt for $4 bil­lion

6 years ago
R&D

It’s not the mon­ey: The lat­est For­tune list of the top 10 bio­phar­mas to work for in­cludes a few sur­prise play­ers

6 years ago
People

No­var­tis eyes a new mar­ket with its buy­out of a small dig­i­tal ther­a­peu­tics play­er

6 years ago
Deals

Covid-19 roundup: HHS of­fi­cial Giroir takes on role of test­ing czar — cue new con­tro­ver­sy; Wuhan lab ve­he­ment­ly ...

6 years ago
Coronavirus

In­cyte nabs 2nd ever ap­proval ahead of sched­ule as FDA in­sists it can still re­view on time

6 years ago
Pharma
FDA+

With third FDA ap­proval, Seat­tle Ge­net­ics plans vir­tu­al launch of metasta­t­ic breast can­cer drug amid coro­n­avirus ...

6 years ago
Pharma
FDA+

Dorothee Kern’s path from bas­ket­ball star to founder of bil­lion-dol­lar biotech(s?); Five Prime Ther­a­peu­tics hands ...

6 years ago
Peer Review

NIH cor­rals bio­phar­ma com­pa­nies, reg­u­la­tors and tri­al net­works to co­or­di­nate Covid-19 R&D

6 years ago
R&D
Coronavirus

Lantern Phar­ma charts course for IPO with AI plat­form that shines light on failed can­cer drugs

6 years ago
Financing
Startups

Chi­nese an­ti­body mak­er, famed for Ebo­la cock­tail, notch­es $160M as it fo­cus­es on can­cer, au­toim­mune drugs

6 years ago
Financing
China

Re­port on one PhI­II remde­sivir study sends in­vestors in­to over­drive, adding bil­lions to Gilead­'s mar­ket cap

6 years ago
R&D
Coronavirus

Covid-19 roundup: Trump changes tune with plan to lift re­stric­tions; FDA in­di­cates its non-coro­n­avirus pace may take ...

6 years ago
Coronavirus

BAR­DA bets $483M on Mod­er­na’s Covid-19 vac­cine as the biotech plots ul­tra-fast PhI­II, re­cruit­ing 150 staffers to ...

6 years ago
Deals
Coronavirus

Covid-19 vac­cine track­er up­dat­ed to in­clude GSK/Sanofi col­lab­o­ra­tion

6 years ago
FDA+
Coronavirus

Gala­pa­gos finds Pol­ish part­ner for in­flam­ma­tion drugs; Zai Lab's Ze­ju­la app gets speedy re­view in Chi­na

6 years ago
News Briefing
First page Previous page 843844845846847848849 Next page Last page
A service from the Financial Times